Summit Therapeutics Inc.
SMMT
Rankning i aktier
#1681
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Aktiekurs
$16.11
Marknadsvärde
$12.85B
Förändring (1 dag)
0.09%
Förändring (1 år)
-14.06%
Land
US
Handel Summit Therapeutics Inc. (SMMT)
Kategori
Healthcare
Historik för aktiesplit för Summit Therapeutics Inc. (SMMT)
Aktien Summit Therapeutics Inc. (symbol: SMMT) har genomgått totalt 0 aktiesplitar.
Den senaste spliten skedde den Oct 21, 2026.
En SMMT-aktie köpt före Oct 21, 2026 motsvarar nu 0 SMMT-aktier.
Den senaste spliten skedde den Oct 21, 2026.
En SMMT-aktie köpt före Oct 21, 2026 motsvarar nu 0 SMMT-aktier.
Lista över aktiesplitar
| År | Split | Multipel | Kumulativ multipel |
|---|---|---|---|
| Inte tillräckligt med data för de angivna datumen. | |||
Aktiesplitar för liknande företag eller konkurrenter
| Företag | Antal aktiesplitar | Kumulativ multipel | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
